AMP-303 is under clinical development by Amplifica Holdings Group and currently in Phase I for Androgenic Alopecia. According to GlobalData, Phase I drugs for Androgenic Alopecia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AMP-303 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMP-303 overview
AMP-303 is under development for the treatment of androgenic alopecia.
Amplifica Holdings Group overview
Amplifica Holdings Group (Amplifica), is a biopharmaceutical company advancing the development of its proprietary compounds for the treatment of androgenic alopecia (hair loss) in both male and female patients.
For a complete picture of AMP-303’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
